The beat-and-raise quarter with accelerating price, 300 bps gross margin expansion, and leverage milestone below 3.0x signals strong operational momentum. Watch Q4 guidance for 4%-6% organic CC growth and the 2027 algorithm re-commitment for sustained mid-single digit top-line growth.
Drug in focus
ELAN drug pipeline →AdTab
● Neutral Named in this 8-K- Impact
- Phase
- Approved/Marketed
- Time to market
- Already launched and marketed in Europe (Spain, Portugal, Austria) since 2023-2024.
- Next catalyst
- None dated
What to watchAdTab is a minor regional brand extension of Elanco's lotilaner (Credelio) franchise, launched in select European markets. It faces heavy competition from established flea/tick brands (Bravecto, NexGard, Simparica) and Elanco's own Credelio line. No upcoming binary catalysts exist for this specific product; watch Elanco's broader pet health portfolio (Credelio Quattro, Zenrelia) for material drivers.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $25.74entry
- T+1 · 8d ago +4.27%α +1.91% · $26.84
- T+5 · 4d ago +4.04%α +1.45% · $26.78
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elanco reported Q3 2026 revenue of $1.265B (+11% YoY, +9% organic constant currency) and adjusted EPS of $0.27, beating consensus of $0.20. The company raised full-year 2026 revenue guidance to $5.155B-$5.18B, adjusted EBITDA to $1.05B-$1.065B, and adjusted EPS to $1.17-$1.20, all above prior ranges. Adjusted gross margin expanded 300 bps YoY to 56.1%, and net leverage improved to 2.9x, unlocking capital allocation flexibility.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $1.265B, +11% YoY reported, +9% organic constant currency
- Adjusted EPS $0.27 vs consensus $0.20, a 35% beat
- Full-year 2026 revenue guidance raised to $5.155B-$5.18B (from $5.09B-$5.14B)
- Full-year 2026 adjusted EPS guidance raised to $1.17-$1.20 (from $1.10-$1.16)
- Adjusted gross margin 56.1%, +300 bps YoY
- Net leverage ratio improved to 2.9x from 3.1x at Q2 2026
- Pet Health revenue +14% YoY; Farm Animal +6% YoY
- Price accelerated to 4% growth in Q3, exceeding expectations
- Zenrelia and Credelio Quattro reached new market share highs in September
- 2027 early outlook: mid-single digit organic CC revenue growth, high-single digit adjusted EBITDA growth, low-double digit adjusted EPS growth
Financial Impact
Revenue beat consensus by ~$55M (4.5%); adjusted EPS beat by $0.07 (35%); full-year guidance raised across all metrics
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Pet Health | $608.0M | +14.0% |
| Farm Animal | $631.0M | +6.0% |
| Cattle | $339.0M | +17.0% |
| Poultry | $201.0M | -7.0% |
| Swine | $91.0M | +5.0% |
| Contract Manufacturing and Other | $26.0M | +136.0% |
Risk Factors
- Poultry revenue declined 7% YoY, a potential headwind from the farm animal segment
- Seresto revenue negatively impacted by U.S. retailer inventory drawdown
- Operating expenses up 12% YoY, driven by launch investments and compensation
- Forward-looking statements on 2027 algorithm are aspirational and subject to competitive and macro risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001739104-26-000054 |
| Document: elan-20261106.htm | 0001739104-26-000054 |
| Document: 0001739104-26-000054-index-headers.html | 0001739104-26-000054 |
| Document: 0001739104-26-000054-index.html | 0001739104-26-000054 |
| Document: 0001739104-26-000054.txt | 0001739104-26-000054 |
| 8-K Data (Synthetic) | 0001739104-26-000054 |
Track record
19 reports on ELAN
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
- Nov 6, 202610d ago 8-K Bullish 6/10 Viewing Entry $25.74 Now $26.41 +2.60% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
- Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
- Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
- Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers